Oh H, El Amin N, Davies T, Appelbaum P C, Edlund C
Department of Microbiology, Pathology and Immunology, Division of Clinical Bacteriology, Karolinska Institutet, Huddinge University Hospital, 141 86 Stockholm, Sweden.
Antimicrob Agents Chemother. 2001 Jul;45(7):1977-81. doi: 10.1128/AAC.45.7.1977-1981.2001.
Mutations in the gyrA gene contribute considerably to quinolone resistance in Escherichia coli. Mechanisms for quinolone resistance in anaerobic bacteria are less well studied. The Bacteroides fragilis group are the anaerobic organisms most frequently isolated from patients with bacteremia and intraabdominal infections. Forty-four clinafloxacin-resistant and-susceptible fecal and clinical isolates of the B. fragilis group (eight Bacteroides fragilis, three Bacteroides ovatus, five Bacteroides thetaiotaomicron, six Bacteroides uniformis, and 22 Bacteroides vulgatus) and six ATCC strains of the B. fragilis group were analyzed as follows: (i) determination of susceptibility to ciprofloxacin, levofloxacin, moxifloxacin, and clinafloxacin by the agar dilution method and (ii) sequencing of the gyrA quinolone resistance-determining region (QRDR) located between amino acid residues equivalent to Ala-67 through Gln-106 in E. coli. Amino acid substitutions were found at hotspots at positions 82 (n = 15) and 86 (n = 8). Strains with Ser82Leu substitutions (n = 13) were highly resistant to all quinolones tested. Mutations in other positions of gyrA were also frequently found in quinolone-resistant and -susceptible isolates. Eight clinical strains that lacked mutations in their QRDR were susceptible to at least two of the quinolones tested. Although newer quinolones have good antimicrobial activity against the B. fragilis group, quinolone resistance in B. fragilis strains can be readily selected in vivo. Mutational events in the QRDR of gyrA seem to contribute to quinolone resistance in Bacteroides species.
gyrA基因的突变在很大程度上导致了大肠杆菌对喹诺酮类药物的耐药性。厌氧菌对喹诺酮类药物的耐药机制研究较少。脆弱拟杆菌群是最常从菌血症和腹腔内感染患者中分离出的厌氧菌。对44株脆弱拟杆菌群的耐克林沙星和敏感的粪便及临床分离株(8株脆弱拟杆菌、3株卵形拟杆菌、5株多形拟杆菌、6株均匀拟杆菌和22株普通拟杆菌)以及6株脆弱拟杆菌群的ATCC菌株进行了如下分析:(i)采用琼脂稀释法测定对环丙沙星、左氧氟沙星、莫西沙星和克林沙星的敏感性,以及(ii)对位于大肠杆菌中相当于Ala-67至Gln-106氨基酸残基之间的gyrA喹诺酮耐药决定区(QRDR)进行测序。在第82位(n = 15)和第86位(n = 8)的热点位置发现了氨基酸替代。具有Ser82Leu替代的菌株(n = 13)对所有测试的喹诺酮类药物高度耐药。在耐喹诺酮和敏感分离株中也经常发现gyrA其他位置的突变。8株QRDR未发生突变的临床菌株对至少两种测试的喹诺酮类药物敏感。尽管新型喹诺酮类药物对脆弱拟杆菌群具有良好的抗菌活性,但脆弱拟杆菌菌株的喹诺酮耐药性在体内很容易被选择出来。gyrA的QRDR中的突变事件似乎导致了拟杆菌属物种对喹诺酮类药物的耐药性。